ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases

3 April 2017 BARCELONA, SPAIN and CAMBRIDGE MA. • Data allows establishment of a safe administration scheme for long term efficacy studies Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented last Friday preliminary data on the First in Human clinical trial of ORY-2001 at the 13th international Conference on Alzheimer’s and Parkinson’s disease celebrated in Vienna, Austria. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗